Sort
10,766 grants matching “checkpoint inhibitor”
DNA repair gene mutations and prostate cancer
$683,795Binghui Shen · Beckman Research Institute/City Of Hope · R01 · FY2022 · CA
The Epigenetic Enzyme CARM1 as a Negative Regulator of Dendritic cells and CD8 T cells in Melanoma
$683,670Kai W Wucherpfennig · Massachusetts General Hospital · P01 · FY2025 · CA
Evolution of gliomas during treatment and resistance
$683,652Rameen Beroukhim · Dana-Farber Cancer Inst · R01 · FY2022 · CA
Evolution of gliomas during treatment and resistance
$683,652Rameen Beroukhim · Dana-Farber Cancer Inst · R01 · FY2023 · CA
N-glycosylation and Immunotherapy for cancer
$683,540Michael Demetriou · University Of California-Irvine · U01 · FY2020 · CA
N-glycosylation and Immunotherapy for cancer
$683,540Michael Demetriou · University Of California-Irvine · U01 · FY2019 · CA
N-glycosylation and Immunotherapy for cancer
$683,540Michael Demetriou · University Of California-Irvine · U01 · FY2018 · CA
Imaging Acidosis and Immune Therapy in PDAC
$683,503Robert J Gillies · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2020 · CA
Imaging Acidosis and Immune Therapy in PDAC
$683,503Shari Pilon-Thomas · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2021 · CA
ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center
$683,484Ticiana Leal · Emory University · UG1 · FY2024 · CA
ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center
$683,484Ticiana Leal · Emory University · UG1 · FY2025 · CA
Interrogating Mechanisms of Anti-tumor Immunity in Human Subjects and Murine Models of IDH-Mutant Glioma Treated with All-Trans Retinoic Acid and PD-1 Inhibition
$683,099Nduka Mgbechinyere Amankulor · University Of Pennsylvania · R37 · FY2023 · CA
Reproducible and Accurate PD-L1 Immunohistochemistry Biomarker Quantification Using Virtual Multiplex Immunofluorescence Restaining
$683,089Saad Nadeem · Sloan-Kettering Inst Can Research · R37 · FY2025 · CA
Genomic and environmental drivers of HCC in Non-Hispanic Blacks: Nature and nurture
$682,915Andrea D. Branch · Icahn School Of Medicine At Mount Sinai · U01 · FY2025 · CA
Image-guided cancer therapy using heat activatable CAR T cells
$682,800Stanislav Y Emelianov · Georgia Institute Of Technology · R01 · FY2022 · EB
Targeting T cell dysfunction in glioblastoma: A proof-of-concept Phase 0/I trial of anti-TIGIT antibody AB154 in combination with anti-PD1 antibody AB122
$682,689David A. Hafler · Yale University · R01 · FY2025 · CA
Project 1: Transgenic TCR-mediated tumor therapy
$682,429Philip D Greenberg · University Of Washington · P01 · FY2021 · CA
Understanding and Overcoming Resistance to Cancer Immunotherapy Due to Defective Antigen Presentation
$682,315Katerina Abigail Politi · Yale University · R01 · FY2021 · CA
Mechanisms driving acute and chronic kidney function decline after immune checkpoint inhibitor therapy for cancer
$682,247Meghan E. Sise · Massachusetts General Hospital · R01 · FY2024 · DK
Pathway inhibitors in Lymphomas
$682,027Mark Roschewski · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Conserved Element DNA Vaccine
$681,593Barbara Felber · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Cytokine-mediated regulation of immunity and microenvironment in colorectal cancer metastasis
$681,537Sergei I Grivennikov · Cedars-Sinai Medical Center · R01 · FY2025 · CA
Cytokine-mediated regulation of immunity and microenvironment in colorectal cancer metastasis
$681,537Sergei I Grivennikov · Cedars-Sinai Medical Center · R01 · FY2024 · CA
Epigenetic Therapy for Thoracic Malignancies
$681,523David Schrump · Division Of Clinical Sciences - Nci · ZIA · FY2021 · CA
Neoantigen-specific T cell responses for Fibrolamellar Hepatocellular Carcinoma
$681,501Mark Yarchoan · Johns Hopkins University · R01 · FY2024 · CA